Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.28 USD
+0.05 (4.07%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PACB 1.28 +0.05(4.07%)
Will PACB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PACB
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Other News for PACB
Sideways movement on September 17 results in no shift to PACB’s technical outlook
Technical picture remains unchanged for PACB after it rises 2.5% on September 16
Technical picture remains unchanged for PACB after it rises 2.56% on September 15
PACB falls 7.14% on September 12, leaving the technical picture intact
The technical outlook for PACB is unchanged after it rises 3.28% on September 11